查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1472248

综合代谢组测试市场：按测试类型、适应症和最终用户分类：2023-2032 年全球机会分析和产业预测

Comprehensive Metabolic Panel Testing Market By Test Type, By Disease Indication, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 266 Pages | 商品交期: 2-3个工作天内

价格

2022年综合代谢组测试市场价值将达到101亿美元，预计2032年将达到161亿美元，2023年至2032年的复合年增长率为4.8%。

综合代谢检测 (CMP) 是一种测量血液中多种物质的血液检查。全面的代谢组测试可测量血糖水平，从而表明血液中的糖分水平，用于诊断糖尿病和监测原有疾病。 CMP 测试还包括钠、钾和氯等电解质的测试。这些电解质对于维持体液平衡以及正常的神经和肌肉功能（包括收缩能力）非常重要。

综合代谢组测试市场-IMG1

此外，CMP 测试透过测量个别血液中尿素氮 (BUN) 和肌酸酐的含量来研究肾功能，有助于及早发现肾臟问题。例如，丙胺酸胺基转移酶(ALT) 和天门冬胺酸胺基转移酶(AST) 都透过指示肝臟内发生的损伤或疾病来检查肝臟健康状况。总体而言，综合代谢面板提供了关键生理过程的全面概述，并帮助医疗保健专业人员诊断和管理各种医疗状况。

推动综合代谢检测市场成长的因素包括对诊断服务和糖尿病、心血管疾病和中风等慢性疾病的需求不断增加，这些疾病需要准确、及时的诊断工具，例如 CMP 检测。例如，根据美国疾病管制与预防中心 (CDC) 的数据，到 2022 年，美国每 10 名美国中就有 6 名患有糖尿病。因此，糖尿病、心血管疾病和肾臟疾病等疾病的盛行率不断增加，需要定期切片检查，从而推动市场成长。

此外，医疗意识的提高和筛检计画的提高也极大地促进了对综合代谢组（CMP）测试的需求。随着预防性医疗保健在公共卫生工作中的重要性日益增加，它已成为教育人们定期检查的好处的重要组成部分。此类系统促进早期发现和早期疗育，从而培养积极主动的医疗管理习惯并促进市场成长。此外，向预防性医疗保健的转变是推动综合代谢检测市场成长的关键因素。随着医疗保健的发展，人们越来越重视及时医疗保健和早期诊断，这一趋势鼓励个人定期进行健康检查，并在潜在疾病出现更严重的情况之前发现它们，我们优先考虑识别健康风险并推动市场成长。

此外，不断增长的老年人口也增加了对医疗保健和诊断测试的需求。老年人更容易患糖尿病、心臟病和肾臟病等慢性疾病，因此需要更频繁的健康检查和全面的代谢计划来监测整体健康状况并管理慢性疾病。提供全面生化资讯的综合组织学检查对于维持老年人健康和管理这些疾病非常重要。

然而，个人和医疗保健提供者缺乏认识是扩大综合代谢组测试领域的主要障碍。此外，医疗保健行业严格的监管要求和合规标准给实验室和诊断服务供应商带来了挑战，阻碍了市场成长。相较之下，就地检验的扩展可以在现场快速获得结果，为医疗保健专业人员提供便利和更快的决策。市场开拓和采用 CMP 测试作为照护现场解决方案的一部分，尤其是在分散的医疗保健环境中，为市场成长提供了利润丰厚的机会。

综合代谢组测试市场按测试类型、疾病适应症、最终用户和地区进行细分。依测试类型，市场分为蛋白质、电解质、肾臟测试、肝臟测试等。依适应症分为肾臟病、肝病、糖尿病等。依最终用户划分，可分为医院、诊断实验室等。

相关人员的主要利益

  • 该报告提供了 2022 年至 2032 年综合代谢面板测试市场分析的细分市场、当前趋势、估计和动态的定量分析，并确定了主导的综合代谢面板测试市场机会。
  • 我们提供市场研究以及与市场驱动因素、市场限制和市场机会相关的资讯。
  • 波特的五力分析揭示了买家和供应商的潜力，帮助相关人员做出利润驱动的业务决策并加强供应商和买家网路。
  • 对综合代谢组测试市场区隔的详细分析有助于识别市场机会。
  • 每个地区的主要国家都根据其对全球市场的收益贡献绘製了地图。
  • 市场参与者定位有助于基准化分析，并可以清楚地了解市场参与者的当前地位。
  • 该报告包括对区域和全球综合代谢面板测试市场趋势、主要企业、细分市场、应用领域和市场成长策略的分析。

此报告可以客製化（请联络销售人员以了解额外费用和时间表）

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 十字交叉细分市场分析 - 市场规模与预测
  • 公司简介的扩充列表
  • 主要参与者的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 主要影响因素
    • 关键投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章综合代谢组测试市场：依测试类型

  • 概述
  • 蛋白质
  • 电解质
  • 肾臟测试
  • 肝臟检查
  • 其他的

第五章综合代谢组测试市场：按适应症疾病

  • 概述
  • 肾臟疾病
  • 肝病
  • 糖尿病
  • 其他的

第六章综合代谢面板测试市场：依最终用户分类

  • 概述
  • 医院
  • 诊断实验室
  • 其他的

第七章综合代谢组测试市场：按地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 哥伦比亚
    • 阿根廷
    • 其他拉丁美洲
  • 中东/非洲
    • GCC
    • 南非
    • 北非
    • 其他中东/非洲

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2022年主要企业定位

第九章 公司简介

  • Quest Diagnostics
  • Laboratory Corporation of America Holdings
  • F. Hoffmann-La Roche Ltd.
  • ARUP Laboratories
  • Walk-In Lab, LLC.
  • Applied InGENuity Diagnostics
  • Scion Lab Services, LLC
  • Baptist Health
  • My Care Labs
  • Blueprint Genetics
Product Code: A269963

The comprehensive metabolic panel testing market was valued at $10.1 billion in 2022 and is projected to reach $16.1 billion by 2032, registering a CAGR of 4.8% from 2023 to 2032. The comprehensive metabolic panel (CMP) is a blood test that measures several substances in the blood. The comprehensive metabolic panel test measures glucose levels, which indicates the level of sugar in the blood and is used to diagnose diabetes or monitor existing cases. In addition, CMP tests include testing of electrolytes such as sodium, potassium and chloride, which are crucial in maintaining fluid balance and carrying out proper nerve and muscle function such as contractility.

Comprehensive Metabolic Panel Testing Market - IMG1

Furthermore, CMP studies kidney operations through determination of varying amounts of urea nitrogen (BUN) and creatinine in individual's blood contributes early detection of renal problems which drives the demand for CMP testing and supports market growth. For instance, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), both examine liver health by indicating damage or illness occurrence within it. Overall, a comprehensive metabolic panel provides a comprehensive overview of key physiological processes, aiding healthcare professionals in diagnosing and managing various medical conditions.

Factors driving the growth of the comprehensive metabolic panel testing market include increased demand for diagnostic services and chronic conditions such as diabetes, cardiovascular diseases, and stroke that require accurate equipment timely diagnostic tools such as CMP testing essential. For instance, according to the Centers for Disease Control and Prevention (CDC), by 2022, 6 out of 10 adults in the U.S. had diabetes. Thus, the rise in prevalence of conditions such as diabetes, cardiovascular diseases, and kidney diseases requires regular biopsies, which drives the growth of the market.

In addition, rise in health care awareness and screening programs contribute significantly to the need for comprehensive metabolic panel (CMP) test. As preventive healthcare becomes more important in public health initiatives, they have become key components in educating people on the benefits of routine check-ups. These schemes promote early recognition and intervention, thus cultivating proactive management practices regarding healthcare, which fuels market growth. Furthermore, the shift toward preventive healthcare is a key factor driving the comprehensive metabolic panel testing market growth. As healthcare evolves, with a surge in emphasis on prompt healthcare and early diagnosis, this trend encourages individuals to adopt regular health screenings, prioritizing the identification of potential health risks before they manifest in more severe situations, thereby driving market growth.

Moreover, the growing elderly population demands the need for health care and diagnostic testing. Older individuals often require more frequent health check-ups with a comprehensive metabolic program to monitor their overall health and manage chronic conditions as older people are more likely to develop chronic conditions such as diabetes, heart disease and kidney disease. Comprehensive histology, which provides comprehensive biochemical information, is important in maintaining the health of older people and managing these conditions.

However, a lack of awareness among both individuals and healthcare providers poses a significant obstacle to the expansion of the comprehensive metabolic panel testing sector. In addition, stringent regulatory requirements and compliance standards in the healthcare business provide difficulties for laboratories and diagnostic service providers thereby hampering market growth. In contrast, the expansion of point-of-care testing allows for rapid on-site results, providing convenience and quick decision-making for healthcare professionals. Developing and adopting CMP testing as part of point-of-care solutions, particularly in decentralized healthcare settings, provides lucrative opportunity for market growth.

The comprehensive metabolic panel testing market is segmented on the basis of test type, disease indication, end user, and region. By test type, the market is classified into proteins, electrolytes, kidney tests, liver test, and others. By disease indication the market is categorized into kidney diseases, liver diseases, diabetes, and others. By end user, it is segregated into hospitals, diagnostic laboratories, and others.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA). Major key players that operate in the comprehensive metabolic panel testing market are Quest Diagnostics, Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Blueprint Genetics, ARUP Laboratories, Walk-In Lab, LLC., Applied InGENuity Diagnostics, Scion Lab Services, LLC, Baptist Health, and My Care Labs. Key players have adopted acquisition, product approval and product launch as key developmental strategies to improve the product portfolio of the comprehensive metabolic panel testing market.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the comprehensive metabolic panel testing market analysis from 2022 to 2032 to identify the prevailing comprehensive metabolic panel testing market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the comprehensive metabolic panel testing market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global comprehensive metabolic panel testing market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Criss-cross segment analysis- market size and forecast
  • Expanded list for Company Profiles
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Test Type

  • Proteins
  • Electrolytes
  • Kidney Tests
  • Liver Tests
  • Others

By Disease Indication

  • Kidney Diseases
  • Liver Diseases
  • Diabtes
  • Others

By End User

  • Hospitals
  • Diagnostic Laboratories
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Colombia
    • Argentina
    • Rest Of La
  • Middle East and Africa
    • Gcc
    • South Africa
    • North Africa
    • Rest Of Mea

Key Market Players:

    • Quest Diagnostics
    • Laboratory Corporation of America Holdings
    • F. Hoffmann-La Roche Ltd.
    • ARUP Laboratories
    • Walk-In Lab, LLC.
    • Applied InGENuity Diagnostics
    • Scion Lab Services, LLC
    • Baptist Health
    • My Care Labs
    • Blueprint Genetics

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Proteins
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Electrolytes
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Kidney Tests
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Liver Tests
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Others
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Kidney Diseases
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Liver Diseases
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Diabetes
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Diagnostic Laboratories
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Test Type
    • 7.2.3. Market size and forecast, by Disease Indication
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Test Type
      • 7.2.5.1.2. Market size and forecast, by Disease Indication
      • 7.2.5.1.3. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Test Type
      • 7.2.5.2.2. Market size and forecast, by Disease Indication
      • 7.2.5.2.3. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Test Type
      • 7.2.5.3.2. Market size and forecast, by Disease Indication
      • 7.2.5.3.3. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Test Type
    • 7.3.3. Market size and forecast, by Disease Indication
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Test Type
      • 7.3.5.1.2. Market size and forecast, by Disease Indication
      • 7.3.5.1.3. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Test Type
      • 7.3.5.2.2. Market size and forecast, by Disease Indication
      • 7.3.5.2.3. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Test Type
      • 7.3.5.3.2. Market size and forecast, by Disease Indication
      • 7.3.5.3.3. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Test Type
      • 7.3.5.4.2. Market size and forecast, by Disease Indication
      • 7.3.5.4.3. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Test Type
      • 7.3.5.5.2. Market size and forecast, by Disease Indication
      • 7.3.5.5.3. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Test Type
      • 7.3.5.6.2. Market size and forecast, by Disease Indication
      • 7.3.5.6.3. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Test Type
    • 7.4.3. Market size and forecast, by Disease Indication
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Test Type
      • 7.4.5.1.2. Market size and forecast, by Disease Indication
      • 7.4.5.1.3. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Test Type
      • 7.4.5.2.2. Market size and forecast, by Disease Indication
      • 7.4.5.2.3. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Test Type
      • 7.4.5.3.2. Market size and forecast, by Disease Indication
      • 7.4.5.3.3. Market size and forecast, by End User
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Test Type
      • 7.4.5.4.2. Market size and forecast, by Disease Indication
      • 7.4.5.4.3. Market size and forecast, by End User
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Test Type
      • 7.4.5.5.2. Market size and forecast, by Disease Indication
      • 7.4.5.5.3. Market size and forecast, by End User
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Test Type
      • 7.4.5.6.2. Market size and forecast, by Disease Indication
      • 7.4.5.6.3. Market size and forecast, by End User
  • 7.5. Latin America
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Test Type
    • 7.5.3. Market size and forecast, by Disease Indication
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Test Type
      • 7.5.5.1.2. Market size and forecast, by Disease Indication
      • 7.5.5.1.3. Market size and forecast, by End User
      • 7.5.5.2. Colombia
      • 7.5.5.2.1. Market size and forecast, by Test Type
      • 7.5.5.2.2. Market size and forecast, by Disease Indication
      • 7.5.5.2.3. Market size and forecast, by End User
      • 7.5.5.3. Argentina
      • 7.5.5.3.1. Market size and forecast, by Test Type
      • 7.5.5.3.2. Market size and forecast, by Disease Indication
      • 7.5.5.3.3. Market size and forecast, by End User
      • 7.5.5.4. Rest Of La
      • 7.5.5.4.1. Market size and forecast, by Test Type
      • 7.5.5.4.2. Market size and forecast, by Disease Indication
      • 7.5.5.4.3. Market size and forecast, by End User
  • 7.6. Middle East and Africa
    • 7.6.1. Key market trends, growth factors and opportunities
    • 7.6.2. Market size and forecast, by Test Type
    • 7.6.3. Market size and forecast, by Disease Indication
    • 7.6.4. Market size and forecast, by End User
    • 7.6.5. Market size and forecast, by country
      • 7.6.5.1. Gcc
      • 7.6.5.1.1. Market size and forecast, by Test Type
      • 7.6.5.1.2. Market size and forecast, by Disease Indication
      • 7.6.5.1.3. Market size and forecast, by End User
      • 7.6.5.2. South Africa
      • 7.6.5.2.1. Market size and forecast, by Test Type
      • 7.6.5.2.2. Market size and forecast, by Disease Indication
      • 7.6.5.2.3. Market size and forecast, by End User
      • 7.6.5.3. North Africa
      • 7.6.5.3.1. Market size and forecast, by Test Type
      • 7.6.5.3.2. Market size and forecast, by Disease Indication
      • 7.6.5.3.3. Market size and forecast, by End User
      • 7.6.5.4. Rest Of Mea
      • 7.6.5.4.1. Market size and forecast, by Test Type
      • 7.6.5.4.2. Market size and forecast, by Disease Indication
      • 7.6.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Quest Diagnostics
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Laboratory Corporation of America Holdings
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. F. Hoffmann-La Roche Ltd.
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. ARUP Laboratories
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Walk-In Lab, LLC.
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Applied InGENuity Diagnostics
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Scion Lab Services, LLC
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Baptist Health
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. My Care Labs
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Blueprint Genetics
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 02. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR PROTEINS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR ELECTROLYTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR KIDNEY TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR LIVER TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. GLOBAL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 08. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR KIDNEY DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR LIVER DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR DIABTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 13. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 21. U.S. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 22. U.S. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 23. U.S. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. CANADA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 25. CANADA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 26. CANADA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. UK COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 41. UK COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 42. UK COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. ITALY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 44. ITALY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 45. ITALY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 48. SPAIN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 56. JAPAN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 57. JAPAN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 58. JAPAN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. CHINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 60. CHINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 61. CHINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. INDIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 63. INDIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 64. INDIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. AUSTRALIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 66. AUSTRALIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 67. AUSTRALIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH KOREA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 72. REST OF ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 73. REST OF ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. LATIN AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 75. LATIN AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 76. LATIN AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 77. LATIN AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 78. BRAZIL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 79. BRAZIL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 80. BRAZIL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 81. COLOMBIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 82. COLOMBIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 83. COLOMBIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 84. ARGENTINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 85. ARGENTINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 86. ARGENTINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 87. REST OF LA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 88. REST OF LA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 89. REST OF LA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. MIDDLE EAST AND AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 91. MIDDLE EAST AND AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 92. MIDDLE EAST AND AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 93. MIDDLE EAST AND AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 94. GCC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 95. GCC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 96. GCC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 97. SOUTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 98. SOUTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 99. SOUTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 100. NORTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 101. NORTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 102. NORTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 103. REST OF MEA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 104. REST OF MEA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 105. REST OF MEA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 106. QUEST DIAGNOSTICS: KEY EXECUTIVES
  • TABLE 107. QUEST DIAGNOSTICS: COMPANY SNAPSHOT
  • TABLE 108. QUEST DIAGNOSTICS: PRODUCT SEGMENTS
  • TABLE 109. QUEST DIAGNOSTICS: SERVICE SEGMENTS
  • TABLE 110. QUEST DIAGNOSTICS: PRODUCT PORTFOLIO
  • TABLE 111. QUEST DIAGNOSTICS: KEY STRATERGIES
  • TABLE 112. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY EXECUTIVES
  • TABLE 113. LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
  • TABLE 114. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT SEGMENTS
  • TABLE 115. LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICE SEGMENTS
  • TABLE 116. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
  • TABLE 117. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATERGIES
  • TABLE 118. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 119. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 120. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 121. F. HOFFMANN-LA ROCHE LTD.: SERVICE SEGMENTS
  • TABLE 122. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 123. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
  • TABLE 124. ARUP LABORATORIES: KEY EXECUTIVES
  • TABLE 125. ARUP LABORATORIES: COMPANY SNAPSHOT
  • TABLE 126. ARUP LABORATORIES: PRODUCT SEGMENTS
  • TABLE 127. ARUP LABORATORIES: SERVICE SEGMENTS
  • TABLE 128. ARUP LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 129. ARUP LABORATORIES: KEY STRATERGIES
  • TABLE 130. WALK-IN LAB, LLC.: KEY EXECUTIVES
  • TABLE 131. WALK-IN LAB, LLC.: COMPANY SNAPSHOT
  • TABLE 132. WALK-IN LAB, LLC.: PRODUCT SEGMENTS
  • TABLE 133. WALK-IN LAB, LLC.: SERVICE SEGMENTS
  • TABLE 134. WALK-IN LAB, LLC.: PRODUCT PORTFOLIO
  • TABLE 135. WALK-IN LAB, LLC.: KEY STRATERGIES
  • TABLE 136. APPLIED INGENUITY DIAGNOSTICS: KEY EXECUTIVES
  • TABLE 137. APPLIED INGENUITY DIAGNOSTICS: COMPANY SNAPSHOT
  • TABLE 138. APPLIED INGENUITY DIAGNOSTICS: PRODUCT SEGMENTS
  • TABLE 139. APPLIED INGENUITY DIAGNOSTICS: SERVICE SEGMENTS
  • TABLE 140. APPLIED INGENUITY DIAGNOSTICS: PRODUCT PORTFOLIO
  • TABLE 141. APPLIED INGENUITY DIAGNOSTICS: KEY STRATERGIES
  • TABLE 142. SCION LAB SERVICES, LLC: KEY EXECUTIVES
  • TABLE 143. SCION LAB SERVICES, LLC: COMPANY SNAPSHOT
  • TABLE 144. SCION LAB SERVICES, LLC: PRODUCT SEGMENTS
  • TABLE 145. SCION LAB SERVICES, LLC: SERVICE SEGMENTS
  • TABLE 146. SCION LAB SERVICES, LLC: PRODUCT PORTFOLIO
  • TABLE 147. SCION LAB SERVICES, LLC: KEY STRATERGIES
  • TABLE 148. BAPTIST HEALTH: KEY EXECUTIVES
  • TABLE 149. BAPTIST HEALTH: COMPANY SNAPSHOT
  • TABLE 150. BAPTIST HEALTH: PRODUCT SEGMENTS
  • TABLE 151. BAPTIST HEALTH: SERVICE SEGMENTS
  • TABLE 152. BAPTIST HEALTH: PRODUCT PORTFOLIO
  • TABLE 153. BAPTIST HEALTH: KEY STRATERGIES
  • TABLE 154. MY CARE LABS: KEY EXECUTIVES
  • TABLE 155. MY CARE LABS: COMPANY SNAPSHOT
  • TABLE 156. MY CARE LABS: PRODUCT SEGMENTS
  • TABLE 157. MY CARE LABS: SERVICE SEGMENTS
  • TABLE 158. MY CARE LABS: PRODUCT PORTFOLIO
  • TABLE 159. MY CARE LABS: KEY STRATERGIES
  • TABLE 160. BLUEPRINT GENETICS: KEY EXECUTIVES
  • TABLE 161. BLUEPRINT GENETICS: COMPANY SNAPSHOT
  • TABLE 162. BLUEPRINT GENETICS: PRODUCT SEGMENTS
  • TABLE 163. BLUEPRINT GENETICS: SERVICE SEGMENTS
  • TABLE 164. BLUEPRINT GENETICS: PRODUCT PORTFOLIO
  • TABLE 165. BLUEPRINT GENETICS: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN COMPREHENSIVE METABOLIC PANEL TESTING MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN COMPREHENSIVE METABOLIC PANEL TESTING MARKET (2023-2032)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL COMPREHENSIVE METABOLIC PANEL TESTING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR PROTEINS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR ELECTROLYTES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR KIDNEY TESTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR LIVER TESTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR KIDNEY DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR LIVER DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR DIABTES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. COMPREHENSIVE METABOLIC PANEL TESTING MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 27. U.S. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. CANADA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. MEXICO COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. GERMANY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. FRANCE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. UK COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. ITALY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. SPAIN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. REST OF EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. JAPAN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. CHINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. INDIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. AUSTRALIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SOUTH KOREA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. REST OF ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. BRAZIL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. COLOMBIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. ARGENTINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. REST OF LA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. GCC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. SOUTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. NORTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 49. REST OF MEA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 50. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 51. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 52. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 53. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 54. COMPETITIVE DASHBOARD
  • FIGURE 55. COMPETITIVE HEATMAP: COMPREHENSIVE METABOLIC PANEL TESTING MARKET
  • FIGURE 56. TOP PLAYER POSITIONING, 2022